LncRNA Information
ID EL0224 Name BACE1-AS Aliases BACE1-AS1; BACE1AS; NCRNA00177
Species Homo sapiens Chromosome 11 Start site 117290874
End site 117293571 Chain plus Exon NO. 1
Assembly Ensembl Release 89 Class antisense NCBI accession NR_037803
Ensembl ENSG00000278768 Sequence


Disease
Disease Method Sample Expression pattern Dysfunction type Description PMID Source
Alzheimer's disease N/A N/A N/A Interaction The BACE1-antisense transcript (BACE1-AS) regulates BACE1 mRNA and subsequently BACE1 protein expression in vitro and in vivo. BACE1 mRNA expression is under the control of a regulatory noncoding RNA that may drive Alzheimer's disease-associated pathophysiology. 18587408 LncRNADisease
Alzheimer's disease N/A brain samples from Alzheimer's disease patients up-regulated interaction BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the binding site for miR-485-5p 20507594
Alzheimer's disease N/A N/A N/A expression The BACE1-antisense transcript (BACE1-AS) is markedly upregulated in brain samples from AD patients and promotes the stability of the (sense) BACE1 transcript. 21785702 LncRNADisease
Alzheimer's disease N/A N/A N/A regulation It has been shown that misexpression of lncRNAs contributes to numerous diseases. For example, an lncRNA may influence the pathogenesis of Alzheimer's disease. The BACE1-AS can regulate BACE1 mRNA expression. BACE1 mRNA expression is under the control of a regulatory non-coding RNA that may drive Alzheimer's disease-associated pathophysiology 22535282 LncRNADisease
Alzheimer's disease N/A N/A N/A expression BACE1 is one of two peptidases that carry out the initial proteolytic cleavage of APP, allowing it to accumulate in the brain. BACE1AS levels were found to be higher in human subjects with AD, and also in BACE1 transgenic mouse models of AD 22817756 LncRNADisease
Alzheimer's disease N/A N/A N/A expression he accumulation of this protein has been implicated in many neurological disorders and elevated levels of both BACE1 and BACE1-AS have been detected in subjects with Alzheimer's disease 22928560 LncRNADisease
Alzheimer's disease N/A N/A N/A expression BACE1-AS is elevated in brains of patients with AD, suggesting that the lncRNA is the driving force behind BACE1 dysregulation in AD 23562612 LncRNADisease
Alzheimer's disease N/A N/A N/A regulation Genomic context links lncRNAs to disease genes/loci and related pathways 23791884 LncRNADisease
Inclusion body myositis N/A N/A N/A regulation Genomic context links lncRNAs to disease genes/loci and related pathways 23791884 LncRNADisease
Alzheimer's disease N/A N/A N/A expression The expression of BACE1 antisense transcript (BACE1-AS) was linked to increased amyloid-β 1–42 in patients with Alzheimer’s disease and gave rise for a stabilizing function of the lncRNA. 24531795 LncRNADisease
Alzheimer's disease N/A N/A N/A regulation In Alzheimer disease, the protein-coding gene BACE-1 (β-site amyloid precursor protein-cleaving enzyme) cleaves amyloid precursor protein (APP) to β-amyloid peptide (Aβ), the accumulation of which (amyloid plaques) is associated with disease. LncRNA BACE1-AS, located on the antisense strand to BACE1, binds complementarily to BACE1 mRNA, increases its stability, regulates BACE1 translation, and thereby the production of Aβ. 24667321 LncRNADisease
colon cancer qPCR etc. cell lines (SNU-C4R, SNU-C5R etc.) down-regulated regulation We selected three lncRNAs, snaR, BACE1AS, and PRAS, and we detected their expression by RT-qPCR using specific primer sets. SnaR and BACE1AS were significantly down-regulated in both resistant cell lines (SNU-C4R and SNU-C5R), whereas PRAS was down-regulated in SNU-C4R cells but not in SNU-C5R cells. Down-regulation of snaR decreased cell death after 5-FU treatment, which indicates that snaR loss decreases in vitro sensitivity to 5-FU. 25078450 Lnc2Cancer
ovarian cancer siRNA human anisomycin-treated ovarian cancer stem cells (OCSCs) up-regulated interaction lncRNA BACE1-AS as a novel target for anisomycin. Elevation of lncRNA BACE1-AS expression is a potential mechanism for suppressing human OCSC proliferation and invasion. 26783004
 


Interaction
Interaction target Level of interaction Type of interaction Description PMID Source
APP RNA-Protein regulation BACE1-AS is directly implicated in the increased abundance of Aβ 1–42 in Alzheimer’s disease. 18587408 LncRNADisease
BACE1 RNA-RNA regulation The BACE1-antisense transcript (BACE1-AS) regulates BACE1 mRNA and subsequently BACE1 protein expression in vitro and in vivo.expression of BACE1-AS increases BACE1 mRNA stability. 18587408 LncRNADisease
BACE1 RNA-RNA co-expression We report here that BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the binding site for miR-485-5p. Indeed, miR-485-5p and BACE1-antisense compete for binding within the same region in the open reading frame of the BACE1 mRNA. 20507594 LncRNADisease
miR-485-5p RNA-RNA regulation We report here that BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the binding site for miR-485-5p. Indeed, miR-485-5p and BACE1-antisense compete for binding within the same region in the open reading frame of the BACE1 mRNA. 20507594 LncRNADisease
miR-485-5p RNA-RNA binding masking the binding site for miR-485-5p 20507594
BACE1 RNA-DNA regulation When expression of lncRNA BACE1-AS was silenced using siRNA, BACE1 expression was downregulated and the antiproliferative and anti-invasive effects of anisomycin were reduced. 26783004